

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER MATSUDA 13
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/807190 ✓
INTERNATIONAL APPLICATION NO. PCT/JP99/05596 ✓	INTERNATIONAL FILING DATE 12 October 1999 ✓	PRIORITY CLAIMED 12 October 1998 ✓
TITLE OF INVENTION POLYMER COMBINING WITH PHOSPHORIC ACID AND PREPARATION CONTAINING THE SAME ✓		
APPLICANT(S) FOR DO/EO/US Katsuya MATSUDA et al.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 00/22008). <input checked="" type="checkbox"/> Courtesy copy of the International Preliminary Examination Report. There were no annexes. <input checked="" type="checkbox"/> Formal drawings, 1 sheets, Figures 1 - 2. <input checked="" type="checkbox"/> Courtesy Copy of the International Search Report. 		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/807190		International Application No. PCT/JP99/05596		Attorney's Docket No. MATSUDA 13	
---	--	--	--	--	--

<p>17. [xx] The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p> <p style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:30%;">Claims as Originally Presented</th> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:15%;"></th> </tr> <tr> <td>Total Claims</td> <td>15 - 20</td> <td></td> <td>X \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent Claims</td> <td>3 - 3</td> <td></td> <td>X \$80.00</td> <td>\$</td> </tr> <tr> <td>Multiple Dependent Claims (if applicable)</td> <td></td> <td></td> <td>+\$270.00</td> <td>\$</td> </tr> </table> <p style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:30%;">Claims After Post Filing Prel. Amend</th> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:15%;"></th> </tr> <tr> <td>Total Claims</td> <td>- 20</td> <td></td> <td>X \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent Claims</td> <td>- 3</td> <td></td> <td>X \$78.00</td> <td>\$</td> </tr> </table> <p style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</p> <p>Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.</p> <p style="text-align: right;">SUBTOTAL =</p> <p>Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> <p style="text-align: right;">TOTAL NATIONAL FEE =</p> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> <p style="text-align: right;">TOTAL FEES ENCLOSED =</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:60%;"></td> <td style="width:20%; text-align: right;">Amount to be:</td> <td style="width:20%; text-align: center;">\$</td> </tr> <tr> <td></td> <td style="text-align: right;">refunded</td> <td></td> </tr> <tr> <td></td> <td style="text-align: right;">charged</td> <td style="text-align: center;">\$</td> </tr> </table>	Claims as Originally Presented	Number Filed	Number Extra	Rate		Total Claims	15 - 20		X \$18.00	\$	Independent Claims	3 - 3		X \$80.00	\$	Multiple Dependent Claims (if applicable)			+\$270.00	\$	Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate		Total Claims	- 20		X \$18.00	\$	Independent Claims	- 3		X \$78.00	\$		Amount to be:	\$		refunded			charged	\$	<p style="text-align: center;">CALCULATIONS PTO USE ONLY</p>
Claims as Originally Presented	Number Filed	Number Extra	Rate																																										
Total Claims	15 - 20		X \$18.00	\$																																									
Independent Claims	3 - 3		X \$80.00	\$																																									
Multiple Dependent Claims (if applicable)			+\$270.00	\$																																									
Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate																																										
Total Claims	- 20		X \$18.00	\$																																									
Independent Claims	- 3		X \$78.00	\$																																									
	Amount to be:	\$																																											
	refunded																																												
	charged	\$																																											

a. [] A check in the amount of \$ _____ to cover the above fees is enclosed.

b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 860.00, is attached.


c. [] Please charge my Deposit Account No. **02-4035** in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

d. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment
 to Deposit Account No. **02-4035**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or
 (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, N.W., SUITE 300
WASHINGTON, D.C. 20001
TEL: (202) 628-5197
FAX: (202) 737-3528
Date of this submission: April 10, 2001


 SIGNATURE
Roger L. Browdy
 NAME
25,618
 REGISTRATION NUMBER

09/807190

JCO8 Rec'd PCT/PTO 10 APR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit:
Katsuya MATSUDA et al.)
)
)
)
)
IA No.: PCT/JP99/05596)
) Washington, D.C.
IA Filed: 12 October 1999)
)
U.S. App. No.:)
(Not Yet Assigned))
) April 10, 2001
National Filing Date:)
(Not Yet Received))
)
For: POLYMER COMBINING WITH...) Docket No.: MATSUDA 13

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and
prior to calculation of the filing fee, kindly amend as
follows:

IN THE SPECIFICATION

After the title please insert the following
paragraph:

REFERENCE TO RELATED APPLICATIONS

--The present application is the national stage
under 35 U.S.C. §371 of international application
PCT/JP99/05596, filed 12 October 1999 which designated the

09807190-041001

In re of: Katsuya MATSUDA et al. (MATSUDA 13)

United States, and which application was not published in the English language.--


REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By:


Roger L. Browdy
Registration No. 25,618

RLB:wrd

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

09807190-041001

1/PRTS

SPECIFICATION

PHOSPHATE-BINDING POLYMER AND TABLETS USING THE SAME
TECHNICAL FIELD

This invention relates to a phosphate-binding polymer
5 and tablets containing it, as well as a process for
producing the tablets.

BACKGROUND ART

Phosphate-binding polymers are non-absorptive polymers
having a phosphate adsorbing capability and they are
10 useful as remedies for hyperphosphatemia induced by renal
hypofunction such as chronic renal failure. As described
in, for example, U.S. Patent No. 5496545 (Japanese Domestic
Announcement Hei 9-504782), phosphate-binding polymers are
publicly known as polycationic polymer compounds comprising
15 primary and secondary amines which are prepared by
crosslinking polyallylamine with a crosslinking agent such
as epichlorohydrin.


According typically to the USP, supra,
phosphate-binding polymer preparations as remedies for
20 hyperphosphatemia can be formulated into tablets using
various additives including crystalline cellulose.
However, said USP presents no specific example of tablet
formulations. Although the present inventors attempted to
produce tablets by blending various additives with the
25 phosphate-binding polymers obtained by the method described
in the USP, no tablets could successfully be produced.

Moreover, known adsorbents for oral administration, as
exemplified by a calcium polystyrene sulfonate preparation

- (KalimateTM manufactured by Nikken Chemicals Co., Ltd.), a sodium polystyrene sulfonate preparation (KayexalateTM manufactured by Torii & Co., Ltd.), an adsorptive charcoal preparation (KremezinTM manufactured by Kureha Chemical Industry Co., Ltd), a cholestyramine preparation (QuestranTM manufactured by Bristol-Myers Squibb Co.) and a precipitated calcium carbonate preparation (manufactured by Emisu Yakuhin K.K.), are all in dosage forms of bulk powders, powder preparation or capsules containing powders.
- 10 Namely, there have been reported no examples of oral adsorbents in the form of tablets.

DISCLOSURE OF THE INVENTION

The phosphate-binding polymer of the present invention is preferably represented by the formula



- 15 [where the molar ratio of (a+b) to c is from 45:1 to 2:1 and m is an integer] and has a true specific gravity of 1.18 - 1.24.

The tablets of the invention comprise the particles

of a phosphate-binding polymer in optional presence of crystalline cellulose and/or low substituted hydroxypropyl cellulose; the particles have an average particle size of no more than 400 μm , with at least 90% being occupied by particles no larger than 500 μm , have a water content of 1 - 14% and are obtained by grinding a phosphate-binding polymer having a true specific gravity of 1.18 - 1.24, preferably 1.20 - 1.22. The tablets show adequate tablet hardness and exhibit rapid disintegrability and dispersibility, as well as high phosphate-binding capability.

The present invention also relates to a process for producing such tablets by compressing the above-defined particles of phosphate-binding polymer into tablets, optionally together with crystalline cellulose and/or low substituted hydroxypropyl cellulose.

When administered orally, phosphate-binding polymers adsorb phosphorus in foods and are excreted into the feces to thereby inhibit the absorption of phosphorus via the digestive tracts, thus controlling the serum phosphorus level. These phosphate-binding polymers are taken in a relatively large single dose, i.e., from 1 to 2 g. Because of reacting with water and thus swelling rapidly, the phosphate-binding polymers can be hardly taken as such.

What is more, tablets prepared by compressing the conventional phosphate-binding polymers without additives have only insufficient tablet hardness, so it has been essential to incorporate substantial amounts of crystalline

cellulose and/or low substituted hydroxypropyl cellulose.

Patients with dialysis who need be administered the phosphate-binding polymers as remedies for hyperphosphatemia are often required to take in limited amounts of water. It is therefore required to develop phosphate-binding polymer preparations in dosage forms that can be taken with small amounts of water. One of the promising dosage forms is tablets which can be reduced in size by compression and coated tablets are preferred since they will not disintegrate in the mouth and can be ingested smoothly. However, when processed into tablets by compressing, a phosphate-binding polymer alone gives only poor tablet hardness and thus cannot be processed as such into a tablet preparation. Further, due to the high hygroscopicity and swelling properties of the phosphate-binding polymer, it is also impossible to produce a phosphate-binding polymer preparation by a process comprising wet granulation using water or a binder solution containing alcohols, etc. and subsequent drying.

In order to overcome these problems, it has been required to develop a production process which comprises blending a powdery phosphate-binding polymer with powdery additives having excellent molding characteristics and compressing the obtained mixture. Such a preparation should be designed by taking into consideration changes in the disintegration properties and dispersibility accompanying the compression. Since a phosphate-binding polymer is to be taken in a relatively large single dose,

special regard should be paid to give a preparation with a high content of the active component.

The present inventors attempted to produce phosphate-binding polymer preparations in the form of tablets by

5 using the various additives described in USP 5496545, but they could not produce any favorable tablets which contain phosphate-binding polymer having a sufficient hardness, a rapid disintegrative dispersibility and an ability to bind to phosphate.

10 Under these circumstances, the present inventors have conducted intensive studies in order to solve the above-mentioned problems. As a result, they have successfully found that by using a phosphate-binding polymer having certain properties on its own, phosphate-binding polymer
15 tablets substantially consisting of the phosphate-binding polymer in the absence of additives could be obtained that had adequate hardness and which exhibited rapid disintegrability and dispersibility, as well as high phosphate-binding capability in an acid to neutral region.

20 The present invention has been accomplished on the basis of this finding.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing the disintegration characteristics of the phosphate-binding polymer
25 preparation of Example 3 in terms of the relationship between the number of strokes by a disintegration tester and the tablet hardness); and

Fig. 2 is a graph showing the phosphate-binding

profile of the phosphate-binding polymer preparation of Example 4.


MODE FOR CARRYING OUT THE INVENTION

The present inventors found that excellent
5 characteristics were exhibited by tablets that contained the particles of a phosphate-binding polymer either alone or in combination with crystalline cellulose and/or low substituted hydroxypropyl cellulose as specified additives, provided that the phosphate-binding polymer particles had a
10 true specific gravity of 1.18 - 1.24, preferably 1.20 - 1.22, an average particle size of no more than 400 μm , preferably no more than 250 μm , with at least 90% being occupied by particles no larger than 500 μm , preferably no larger than 300 μm , and a water content of 1 - 14%. The
15 stated values of true specific gravity were measured with a true specific gravity meter Accupyc Model 1330 of Shimadzu Corp.

The phosphate-binding polymer to be used in the invention may be prepared on the basis of the process
20 described in USP 5496545, supra. In that process, a specified polymer is crosslinked with a specified crosslinker in the presence of solvent water. According to the present invention, the phosphate-binding polymer having a true specific gravity in the stated range can be produced
25 by replacing water with a mixed solvent system consisting of water and acetonitrile in a volume ratio which usually ranges from 10:90 to 90:10, preferably from 40:60 to 60:40.

The thus obtained phosphate-binding polymer is dried

and ground into particles having an average particle size of no more than 400 μm , preferably no more than 250 μm , with at least 90% being occupied by particles no larger than 500 μm , preferably no larger than 300 μm . The particles are then adjusted to 1 - 14% in water content. Among the phosphate-binding polymers thus prepared, a crosslinked polymer obtained by treating polyallylamine with epichlorohydrin is particularly suitable for use in the present invention. This polymer is represented by the formula



[where the molar ratio of (a+b) to c is from 45:1 to 2:1, preferably from 20:1 to 4:1, more preferably from about 10:1 to 8:1, the most preferably about 9:1, and m is an integer].

Since the phosphate-binding polymer of the invention is a crosslinked polymer, m in the above formula is a large integer that represents the network structure of the crosslinked and extended polymer and can theoretically be

as great as 1×10^7 . Since this polymer is crosslinked in a network, each of the particles into which it has been ground is in effect a single molecule; therefore, the molecular weight of the polymer is equivalent to the weight of an individual polymer particle.

If the true specific gravity of the phosphate-binding polymer is greater than 1.24, tablets compressed from this polymer alone do not have adequate hardness. Phosphate-binding polymers whose true specific gravity is less than 1.18 are not suited to handling in industrial applications. Particles having a greater average particle size than 400 μm are not preferred since they do not have the necessary sufficient hardness to be compressed into tablets. If the water content of the phosphate-binding polymer is less than 1%, it again fails to have the necessary sufficient hardness to permit compression into tablets and if any tablets are formed, their surfaces are liable to abrasion. If the water content of the phosphate-binding polymer exceeds 14%, it has sufficient hardness to permit compressing into tablets but, on the other hand, the resulting tablets undergo plastic deformation to become no longer suitable as pharmaceutical preparations. In order that the tablets can be taken more smoothly, they must have a hardness that gives a reading of at least 6 KP on a tablet hardness meter and a surface strength that gives a weight loss of no more than 1% in a friability test (100 revolutions). What is more, the tablets should not undergo plastic deformation. To meet these requirements, the

phosphate-binding polymer must have a water content in the range of 1 - 14%. The expression "a water content of 1 - 14%" as used herein means that after drying at 105°C for 16 hours, the polymer weight is reduced by 1 - 14%. The preferred drying weight loss of the phosphate-binding polymer ranges from 2 to 14%. If the phosphate-binding polymer per se absorbs moisture in the course of grinding to give a water content of 1 - 14%, there is no particular need to adjust the water content of the polymer and it may be directly used to prepare the tablets of the present invention.

The phosphate-binding polymer may be ground with any known model of mills such as an impact mill that can yield particles no larger than 500 μm and produce an average particle size of no more than 400 μm .

The water content of the phosphate-binding polymer can be adjusted either with a moisture-adjusting agent such as a saturated aqueous solution of sodium chloride (25°C, RH 75.3%), a saturated aqueous solution of calcium chloride (25°C, RH 84.3%) or a saturated aqueous solution of magnesium nitrate (25°C, RH 52.8%) or by letting the polymer absorb moisture in the air atmosphere. The phosphate-binding polymer of the desired water content can also be prepared by performing the drying step in its production process in such a way as to give a water content of 1 - 14%.

The crystalline cellulose to be used in the invention is not limited in any particular way and use may be made of

one that gives a weight loss of no more than 7% after drying at 105°C for 3 hours. Preferably, commercial products such as Avicel™ PH101, PH102, PH301, PH302 and Ceolus™ KG-801 (all manufactured by Asahi Chemical Industry Co., Ltd.) may be used either alone or in admixture.

The low substituted hydroxypropyl cellulose that can be used in the invention is such that it has 5.0 - 16.0 wt% substitution by hydroxypropoxyl groups (-OC₃H₆OH).

10 Preferred examples of such low substituted hydroxypropyl cellulose are commercial products such as LH-11, LH-21 and LH-31 (manufactured by Shin-Etsu Chemical Co., Ltd.) that may be used either alone or in admixture.

The amounts of the crystalline cellulose and/or low substituted hydroxypropyl cellulose that are optionally added to the phosphate-binding polymer in the present invention may be set at any values in consideration of the dose of the phosphate-binding polymer to be taken as an oral preparation and the ease with which it can be taken.

15 In a preferred embodiment, for example, the crystalline cellulose or the low substituted hydroxypropyl cellulose is used in an amount of at least 10 wt%, more preferably at least 30 wt%, based on the weight of the phosphate-binding polymer having an average particle size of no more than 250 μm, at least 90% being occupied by particles no larger than 300 μm, and a water content of 1 - 14%. If both of the crystalline cellulose and the low substituted hydroxypropyl cellulose are added, it is preferable that the sum of the

contents of these components is 10 wt% or more, preferably 30 wt% or more. From the viewpoint of the administration properties, etc, of the preparation, the upper limit of the content of the crystalline cellulose and/or the low substituted hydroxypropyl cellulose is in the range of 50 - 200 wt%.

Since the phosphate-binding polymer, the crystalline cellulose and the low substituted hydroxypropyl cellulose produce great frictional forces, it is recommended that a hardened oil be used in a continuous tableting process in order to reduce the load on the tableting machine due to the jarring action of punches. A useful hardened oil is a commercial product such as LubriwaxTM manufactured by Freund Industrial Co., Ltd.

To produce the phosphate-binding polymer tablets of the present invention, the crystalline cellulose and/or low substituted hydroxypropyl cellulose, together with fillers (e.g. lactose, sucrose or mannitol), a lubricant (e.g. magnesium stearate or polyethylene glycol) and other additives conventionally employed in the art, perfumes, coloring agent etc. may be added and mixed with the phosphate-binding polymer and the resulting blend is compressed into tablets.

The phosphate-binding polymer tablets of the invention may be further processed into film-coated tablets by coating their surfaces with a film. In the film coating process, use may be made of water-soluble film bases such as hydroxypropyl methylcellulose and acrylic acid

copolymers. Use of hydroxypropyl methylcellulose is particularly preferred.

The following preparations and examples are provided for further illustrating the present invention but are in
5 no way to be taken as limiting.

[Preparation 1]

Polyallylamine was subjected to crosslinking polymerization in a water/acetonitrile (ca. 50:50 w/w) mixed solvent with epichlorohydrin being added as a
10 crosslinker, thereby producing a polycationic phosphate-binding polymer in which about 40% of the primary amine (81.2 mol%) and secondary amine (18.8 mol%) formed hydrochlorides. The polymer was then vacuum-dried to give a dry powder, which was ground with an impact mill into
15 particles of water-containing phosphate-binding polymers (true specific gravity, 1.209 - 1.211; water content, 2.1 - 2.5%; under 300 μ m size = 99.0 - 99.6%).

[Preparation 2]

Polyallylamine was subjected to crosslinking
20 polymerization in water with epichlorohydrin being added as a crosslinker, thereby producing a polycationic phosphate-binding polymer in which about 40% of the primary amine (81.2 mol%) and secondary amine (18.8 mol%) formed hydrochlorides. The polymer was then dried with air to
25 give a dry powder, which was ground with an impact mill into particles of a water-containing phosphate-binding polymer (true specific gravity, 1.253; water content, 3.6 - 3.8%; under 300 μ m size = 99.3 - 99.7%).

[Example 1]

The particles of the water-containing phosphate-binding polymers obtained in Preparation 1 (to give true specific gravities of 1.209 - 1.211) and those of the polymer obtained in Preparation 2 (to give a true specific gravity of 1.253) were compressed under various static pressures of 500 - 1750 kg into tablets of 10 mm^φ each weighing 300 mg. These tablets were measured for hardness with a hardness meter (Pharmatest). The results are shown in Table 1.

Table 1

	Preparation 1			Preparation 2	
True specific gravity	1.209	1.211	1.211	1.253	1.253
Water content	2.5%	2.1%	2.1%	3.6%	3.8%
Under 300 μm size	99.0%	99.6%	99.3%	99.7%	99.3%
Compressing pressure:					
500 kg	2.1 KP	4.7 KP	2.0 KP	0.5 KP	0.8 KP
750 kg	5.1 KP	9.2 KP	4.0 KP	0.8 KP	1.5 KP
1000 kg	10.8 KP	11.6 KP	8.5 KP	1.3 KP	2.5 KP
1250 kg	13.1 KP	19.0 KP	11.2 KP	2.2 KP	3.5 KP
1500 kg	19.5 KP	20.0 KP	13.8 KP	2.6 KP	4.6 KP
1750 kg	23.9 KP	24.3 KP	15.5 KP	3.6 KP	5.6 KP

As one can see from Table 1, none of the tablets compressed solely from the phosphate-binding polymer with a true specific gravity of 1.253 had adequate hardness (≥ 6 KP) irrespective of the compressing pressure applied; on

the other hand, the tablets compressed from the phosphate-binding polymers with true specific gravities of 1.209 - 1.211 had adequate hardness when they were compressed at pressures of 1000 kg and more.

5 [Example 2]

Two hundred milligrams of the particles of the water-containing phosphate-binding polymer with a true specific gravity of 1.209 which was obtained in Preparation 1 were mixed with 100 mg of an additive crystalline cellulose (Avicel™ PH101 of Asahi Chemical Industry Co., Ltd.) and the blend was compressed under static pressures of 500 kg, 750 kg and 1000 kg into tablets of 10 mm^φ each weighing 300 mg.

These tablets were measured for hardness with a hardness meter. The tablets compressed at a pressure of 750 kg were also tested with a disintegration tester (Toyama sangyo) using water as a test fluid. The results of both tests are shown in Table 2.

Table 2

	Tablet hardness	Disintegration time
Compressing pressure: 500 kg	5.7 KP	20 seconds
750 kg	9.0 KP	
1000 kg	13.6 KP	

As one can see from Table 2, the tablets compressed from the blend of the phosphate-binding polymer and crystalline cellulose at pressures of 750 kg and more had

hardness values of at least 6 KP and exhibited rapid disintegrability.

[Example 3]

To 767.7 g of the particles of the water-containing phosphate-binding polymer with a true specific gravity of 1.209 that was obtained in Preparation 1, 349.5 g of crystalline cellulose, 5.6 g of a hardened oil (Lubriwax™ 101 of Freund) and 2.2 g of a lubricant magnesium stearate (Nitto Kasei) were added and the ingredients were mixed together. The resulting blend was set on a single-action tableting machine (Model N-30 of Okada Seiko) and compressed at 1750 kg into tablets of 10.5 mm^φ each weighing 375 mg. This yielded uncoated tablets each containing about 250 mg of the dry phosphate-binding polymer.

These tablets were measured for hardness with a hardness meter (Contester), which read a value of 10.9 KP. They showed a disintegration time of 67 seconds (test fluid, water).

The tablets each containing 250 mg of the phosphate-binding polymer were coated with a film comprising 8.25 mg of hydroxypropyl methylcellulose 2910 (HPMC TC-5-RW of Shin-Etsu Chemical Co., Ltd.), 1.26 mg of polyethylene glycol 6000 (Nippon Oil and Fats Co., Ltd.), 1.8 mg of titanium oxide (A-100 of Ishihara Sangyo Kaisha, Ltd.) and 0.69 mg of talc. The coating machine was Doria Coater Model DRC-500 of Powrec Corporation.

The film-coated tablets were tested with a

disintegration tester at 1 - 30 strokes per minute using two test solutions (pH 1.2; medium 1st specified in Japan Pharmacopoeia and water). The test results are shown in Fig. 1.

5 As one can see from Fig. 1, the phosphate-binding polymer preparation showed rapid disintegrability in an acidic to neutral region without being affected by the strength of agitation (number of strokes).

[Example 4]

10 Four of the coated tablets prepared in Example 3 each containing 250 mg of the phosphate-binding polymer were subjected to the following simulated evaluation of drug efficacy: 4.7 g of sodium chloride, 21.3 g of N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid and 0.544 g of
15 potassium dihydrogenphosphate were dissolved in water; after pH adjustment to 7, the solution was warmed to 37°C; 200 ml of the thus prepared test solution was stirred with the paddles rotating at 100 rpm to measure the phosphate-binding capability of the polymer. When the tablets
20 disintegrated, the phosphate-binding polymer dispersed to adsorb the phosphate, causing the residual concentration of the phosphate in the test solution to vary with time. The initial phosphate level in the test solution was taken as 1 and the value at the completion of phosphate adsorption as
25 0. The results of the measurement are shown in Fig. 2.


Obviously, the phosphate-binding polymer preparations exhibited rapid phosphate binding capability.

INDUSTRIAL APPLICABILITY

The phosphate-binding polymer of the present invention can be formulated as tablets irrespective of whether it is used alone or combined with additives. Whichever the case, the tablets have satisfactory hardness, contain the active
5 ingredient in high proportion, have high phosphate-binding capability and exhibit rapid disintegrability in an acidic to neutral region while having little sensitivity to the strength of agitation. Therefore, the tablets of the invention are excellent pharmaceutical preparations that
10 undergo reduced variations in bioavailability in spite of movements within the digestive tracts and pH changes.

CLAIMS

1. A phosphate-binding polymer that is represented by the formula



[where the molar ratio of (a+b) to c is from 45:1 to 2:1 and m is an integer] and which has a true specific gravity of 1.18 - 1.24.

2. The phosphate-binding polymer according to claim 1 which has a true specific gravity of 1.20 - 1.22.
3. The phosphate-binding polymer according to claim 1, wherein the molar ratio of (a+b):c is from 20:1 to 4:1.
4. A tablet comprising the particles of a phosphate-binding polymer having an average particle size of no more than 400 μm , with at least 90% being occupied by particles no larger than 500 μm , and having a true specific gravity of 1.18 - 1.24 and a water content of 1 - 14%.
5. The tablet according to claim 4 which has a true specific gravity of 1.20 - 1.22.
6. The tablet according to claim 4, 5 or 6, wherein said

particles of a phosphate-binding polymer have an average particle size of no more than 250 μm , with at least 90% being occupied by particles no larger than 300 μm .

7. The tablet according to any one of claims 1 - 6 which further contains crystalline cellulose and/or low substituted hydroxypropyl cellulose.

8. The tablet according to claim 7, wherein the content of the crystalline cellulose and/or low substituted hydroxypropyl cellulose is at least 10 wt% of the weight of the phosphate-binding polymer.

9. The tablet according to claim 7 or 8, wherein the low substituted hydroxypropyl cellulose has 5.0 - 16.0 wt% substitution by hydroxypropoxyl groups.

10. The tablet according to any one of claims 4 - 9, wherein the phosphate-binding polymer is the one described in U.S. Patent No. 5496545.

11. The tablet according to any one of claims 3 - 9, wherein the phosphate-binding polymer is one that is obtained by allowing epichlorohydrin to act on polyallylamine in a water/acetonitrile mixed solvent system so that the polyallylamine is crosslinked.

12. The tablet according to any one of claims 4 - 11 which further contains a hardened oil.

13. The tablet according to any one of claims 4 - 12 which is coated on the surface with a water-soluble film base.

14. A process for producing phosphate-binding polymer tablets which comprises:

grinding a phosphate-binding polymer having a true

specific gravity of 1.18 - 1.24 into particles having an average particle size of no more than 400 μm , with at least 90% being occupied by particles no larger than 500 μm , said phosphate-binding polymer being either polyallamine or obtained by crosslinking the same;

adjusting the phosphate-binding polymer particles to a water content of 1 - 14%;

mixing the particles with crystalline cellulose and/or low substituted hydroxypropyl cellulose; and



compressing the mixture into tablets.

15. The process according to claim 14, wherein said phosphate-binding polymer is ground into particles having an average particle size of no more than 250 μm , with at least 90% being occupied by particles no larger than 300 μm .

ABSTRACT

Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18 - 1.24, tablets that solely consist of the particles of a phosphate-binding polymer
5 having an average particle size of no more than 400 μ m, with at least 90% being occupied by particles no larger than 500 μ m, and having a true specific gravity of 1.18 - 1.24 and a water content of 1 - 14%, or tablets that contain both the particles and crystalline cellulose and/or
10 low substituted hydroxypropyl cellulose, and a process for producing such tablets.

The phosphate-binding polymer can be formulated as tablets either alone or in combination with specified additives. Whichever the case, the tablets have
15 satisfactory hardness, contain the active ingredient in high proportion, have high phosphate-binding capability and exhibit rapid disintegrability in an acidic to neutral region while having little sensitivity to the strength of agitation. The tablets are excellent pharmaceutical
20 preparations that undergo reduced variations in bioavailability in spite of movements within the digestive tracts and pH changes.

Fig. 1*Fig. 2*

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PHOSPHATE-BINDING POLYMER AND TABLETS USING THE SAME

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appln. No. _____*; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/JP99/05596 filed October 12, 1999, entry requested on _____*; national stage application received U.S. Appln. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

<u>289031/1998</u> ✓	<u>Japan</u>	<u>12/10/1998</u> ✓	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under §119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practioners associated with Customer Number 001444Direct all correspondence to the address associated with Customer Number 001444; i.e.,

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001-5303
(202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from YUASA AND HARA as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

09807190 "041004

Title: PHOSPHATE-BINDING POLYMER AND TABLETS USING THE SAMEU.S. Application filed _____, Serial No. _____
PCT Application filed October 12, 1999, Serial No. PCT/JP99/05596

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR <u>Katsuya MATSUDA</u>		INVENTOR'S SIGNATURE <u>Katsuya Matsuda</u>	DATE Mar. 1, 2001
RESIDENT <u>Tokyo, Japan JPX</u>		CITIZENSHIP Japanese ✓	
POST OFFICE ADDRESS <u>c/o Chugai Seiyaku Kabushiki Kaisha of 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543 Japan</u>			
FULL NAME OF SECOND JOINT INVENTOR <u>Ryuji KUBOTA</u>		INVENTOR'S SIGNATURE <u>Ryuji Kubota</u>	DATE Mar. 1, 2001
RESIDENT <u>Tokyo, Japan JPX</u>		CITIZENSHIP Japanese ✓	
POST OFFICE ADDRESS <u>c/o Chugai Seiyaku Kabushiki Kaisha of 41-8, Takada 3-chome, Toshima-ku, Tokyo 171-8545 Japan</u>			
FULL NAME OF THIRD JOINT INVENTOR <u>Noriyuki TAKATA</u>		INVENTOR'S SIGNATURE <u>Noriyuki Takata</u>	DATE Mar. 1, 2001
RESIDENT <u>Shizuoka, Japan JPX</u>		CITIZENSHIP Japanese ✓	
POST OFFICE ADDRESS <u>c/o Chugai Seiyaku Kabushiki Kaisha of 135, Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513 Japan</u>			
FULL NAME OF FOURTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.